Your browser doesn't support javascript.
loading
Inhibition of RANK signaling in breast cancer induces an anti-tumor immune response orchestrated by CD8+ T cells.
Gómez-Aleza, Clara; Nguyen, Bastien; Yoldi, Guillermo; Ciscar, Marina; Barranco, Alexandra; Hernández-Jiménez, Enrique; Maetens, Marion; Salgado, Roberto; Zafeiroglou, Maria; Pellegrini, Pasquale; Venet, David; Garaud, Soizic; Trinidad, Eva M; Benítez, Sandra; Vuylsteke, Peter; Polastro, Laura; Wildiers, Hans; Simon, Philippe; Lindeman, Geoffrey; Larsimont, Denis; Van den Eynden, Gert; Velghe, Chloé; Rothé, Françoise; Willard-Gallo, Karen; Michiels, Stefan; Muñoz, Purificación; Walzer, Thierry; Planelles, Lourdes; Penninger, Josef; Azim, Hatem A; Loi, Sherene; Piccart, Martine; Sotiriou, Christos; González-Suárez, Eva.
Afiliação
  • Gómez-Aleza C; Oncobell, Bellvitge Biomedical Research Institute, IDIBELL, Barcelona, Spain.
  • Nguyen B; Breast Cancer Translational Research Laboratory J.-C. Heuson, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium.
  • Yoldi G; Marie-Josée and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, 10065, USA.
  • Ciscar M; Oncobell, Bellvitge Biomedical Research Institute, IDIBELL, Barcelona, Spain.
  • Barranco A; Oncobell, Bellvitge Biomedical Research Institute, IDIBELL, Barcelona, Spain.
  • Hernández-Jiménez E; Molecular Oncology, Spanish National Cancer Research Centre (CNIO), Madrid, Spain.
  • Maetens M; Oncobell, Bellvitge Biomedical Research Institute, IDIBELL, Barcelona, Spain.
  • Salgado R; Molecular Oncology, Spanish National Cancer Research Centre (CNIO), Madrid, Spain.
  • Zafeiroglou M; Oncobell, Bellvitge Biomedical Research Institute, IDIBELL, Barcelona, Spain.
  • Pellegrini P; Breast Cancer Translational Research Laboratory J.-C. Heuson, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium.
  • Venet D; Breast Cancer Translational Research Laboratory J.-C. Heuson, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium.
  • Garaud S; Department of Pathology, GZA-ZNA Ziekenhuizen, Antwerp, Belgium.
  • Trinidad EM; Oncobell, Bellvitge Biomedical Research Institute, IDIBELL, Barcelona, Spain.
  • Benítez S; Oncobell, Bellvitge Biomedical Research Institute, IDIBELL, Barcelona, Spain.
  • Vuylsteke P; Breast Cancer Translational Research Laboratory J.-C. Heuson, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium.
  • Polastro L; Molecular Immunology Unit, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium.
  • Wildiers H; Oncobell, Bellvitge Biomedical Research Institute, IDIBELL, Barcelona, Spain.
  • Simon P; Oncobell, Bellvitge Biomedical Research Institute, IDIBELL, Barcelona, Spain.
  • Lindeman G; Department of Medical Oncology, Université Catholique de Louvain, CHU UCL, Namur, site Sainte-Elisabeth, Namur, Belgium.
  • Larsimont D; Department of Medical Oncology, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium.
  • Van den Eynden G; Department of Oncology, KU Leuven-University of Leuven, Leuven, Belgium.
  • Velghe C; Department of Obstetrics and Gynaecology, Erasme, Université Libre de Bruxelles, Brussels, Belgium.
  • Rothé F; Peter MacCallum Cancer Centre, The Walter and Eliza Hall Institute of Medical Research and The Royal Melbourne Hospital, Melbourne, VIC, Australia.
  • Willard-Gallo K; Department of Pathology, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium.
  • Michiels S; Molecular Immunology Unit, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium.
  • Muñoz P; Clinical Trial Supporting Unit, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium.
  • Walzer T; Breast Cancer Translational Research Laboratory J.-C. Heuson, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium.
  • Planelles L; Molecular Immunology Unit, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium.
  • Penninger J; Service de Biostatistique et D'Epidémiologie, Gustave Roussy, CESP, U1018, Université Paris-Sud, Faculté de Médcine, Université Paris-Saclay, Villejuif, France.
  • Azim HA; Oncobell, Bellvitge Biomedical Research Institute, IDIBELL, Barcelona, Spain.
  • Loi S; Centre International de Recherche en Infectiologie, CIRI, Inserm U1111, CNRS, Université Claude Bernard, Lyon, France.
  • Piccart M; BiOncotech Therapeutics, Parc Cientific Universitat, Valencia, Spain.
  • Sotiriou C; Life Sciences Institute, University of British Columbia, Vancouver, BC, Canada.
  • González-Suárez E; IMBA, Institute of Molecular Biotechnology of the Austrian Academy of Sciences, Vienna, Austria.
Nat Commun ; 11(1): 6335, 2020 12 10.
Article em En | MEDLINE | ID: mdl-33303745
Assuntos
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias da Mama / Transdução de Sinais / Linfócitos T CD8-Positivos / Receptor Ativador de Fator Nuclear kappa-B / Imunidade Tipo de estudo: Prognostic_studies Limite: Adult / Animals / Female / Humans / Middle aged Idioma: En Revista: Nat Commun Assunto da revista: BIOLOGIA / CIENCIA Ano de publicação: 2020 Tipo de documento: Article País de afiliação: Espanha País de publicação: Reino Unido
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias da Mama / Transdução de Sinais / Linfócitos T CD8-Positivos / Receptor Ativador de Fator Nuclear kappa-B / Imunidade Tipo de estudo: Prognostic_studies Limite: Adult / Animals / Female / Humans / Middle aged Idioma: En Revista: Nat Commun Assunto da revista: BIOLOGIA / CIENCIA Ano de publicação: 2020 Tipo de documento: Article País de afiliação: Espanha País de publicação: Reino Unido